Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Hepion Pharmaceuticals Inc., formerly known as ContraVir Pharmaceuticals Inc., is based in Edison, New Jersey.